Synergistic Effect of Plasmid Inhibitors and Antimicrobial Drugs Against Clinical MDR-hvKP

Sponsor

Assiut University (Other)

Overall Status

Not yet recruiting

CT.gov ID

NCT05932355

Collaborator

(none)

Enrollment

Anticipated Duration (Months)

Study Details

Study Description

Brief Summary

Screening for MDR-hvKP causing VAP in patients admitted to chest ICU in Assiut University Hospital.
In vitro evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin against clinical MDR-hvKP isolates by checkerboard and time killing assay.
In vivo evaluation of the synergistic activity of combined meropenem/levofloxacin with and without kasugamycin using MDR-hvKP septic rat model.

Condition or Disease	Intervention/Treatment	Phase
Synergy Between Plasmid Inhibitors and Combined Antibiotics

Detailed Description

New "hypervirulent" Klebsiella-pneumoniae (hvKp) strain has emerged as a clinically-significant-pathogen in both healthy and immunocompromised individuals . HvKp, at its discovery, was rarely resistant to antimicrobial-agents , however, nowadays, antibiotic-resistant hvKP isolates are being reported .

Plasmids are important vectors that bacteria use to transfer resistance and virulence determinants. Typically, genetic elements conferring resistance and virulence were encoded by different plasmids . Most recently, clinicians have been faced, the confluence of resistance and virulence-determinants on the same or coexisting-plasmids with the evolution of multidrug-resistant (MDR) and hypervirulent Klebsiella pneumoniae hvKP .

One approach to combat MDR infections is to combine antimicrobial drugs during a treatment-regimen . Fluoroquinolone plus carbapenems is one of-the most useful-combination used in cases which suffer from MDR to most available monotherapies . Another-approach is Plasmid curing, using plasmid inhibitors, which is the method of removing plasmids from the bacterial populations while leaving the population intact leading to reversal of the plasmid-mediated antibiotic resistance .

Kasugamycin, an-aminoglycoside; is a compound exhibiting significant-antiplasmid activity-up-to-complete suppression of plasmid-replication . Kasugamycin was found to block plasmid replication by inhibiting-expression of plasmid replication initiation-protein, RepE, and to reduce plasmid-levels by 90% . Accordingly, we hypothesize that, using dual-antibiotics supplemented with plasmid inhibitor will be efficient in inhibiting MDR-hvKP, both in vitro and in vivo.

This is the first-study to evaluate the effect of addition of plasmid inhibitor on improving the efficacy of antibiotics and improve their synergistic activity. The results of this study will open the door for-using plasmid-inhibitor-compounds on restoring the usefulness of many conventional-antibiotics to which-resistance has emerged.

Study Design

Study Type:

Observational

Anticipated Enrollment :

50 participants

Observational Model:

Cohort

Time Perspective:

Prospective

Official Title:

Assessment of the Effect of Plasmid Inhibitors and Antimicrobial Drugs as Combined Strategy Against Clinical Multi-drug Resistant Hypervirulent Klebsiella Pneumoniae

Anticipated Study Start Date :

Jul 1, 2023

Anticipated Primary Completion Date :

Jul 1, 2025

Anticipated Study Completion Date :

Aug 1, 2025

Outcome Measures

Primary Outcome Measures

Synergistic effect of plasmid inhibitors and antimicrobial drugs against MDR-hvKP invitro. [24hours]
Assessment of synergy invitro by : Checkerboard assay : Fractional inhibitory concentrations index (FICI) will be calculated as: FICI = FIC A (MIC for antibiotic A in combination) / (MIC antibiotic A) + FIC B (MIC antibiotic B in combination) / (MIC antibiotic B). (It is a ratio) Synergy is defined as FICI ≤0.5, no interaction is defined as FICI > 0.5 and ≤ 4, and antagonism is defined as FICI >4 . .

Eligibility Criteria

Criteria

Ages Eligible for Study:

N/A and Older

Sexes Eligible for Study:

All

Inclusion Criteria:

VAP patients (patients under mechanical ventilation for more than 48 h with new or progressive infiltrate on chest X-ray and have at least two of the following criteria:

Fever (>38 oC) with no other recognized cause
WBCs < 4000/mm3 or >12000/mm3
New onset of purulent sputum.
Increase in respiratory secretion or increased need for suctioning.
New-onset or worsening cough, or dyspnea, or tachypnea worsening gas exchange.

Exclusion Criteria:

Patients with chest diseases other than VAP .

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

Assiut University

Investigators

Study Director: Sherine Aly, Professor, Department of Microbiology and Immunology
Study Director: Wegdan Mohamad, Assistant Professor, Department of Microbiology and Immunology

Study Documents (Full-Text)

None provided.

More Information

Publications

Responsible Party:

Shereen Elnokrashy Mohamed, Principal Investigator, Assiut University

ClinicalTrials.gov Identifier:

NCT05932355

Other Study ID Numbers:

Plasmid inhibitors in MDR-hvKP

First Posted:

Jul 6, 2023

Last Update Posted:

Jul 6, 2023

Last Verified:

Jun 1, 2023

Studies a U.S. FDA-regulated Drug Product:

Studies a U.S. FDA-regulated Device Product:

Study Results

No Results Posted as of Jul 6, 2023